MLTX – moonlake immunotherapeutics - class a ordinary shares (US:NASDAQ)

DELAYED


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

YTD

1 Day

MLTX

SPY

QQQ

Swipe to see more

Main News & Impact Reports

Date

Time

Symbol

Headline

Impact

11/14

08:15 am

mltx

MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.

Low Report

MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.

Report

11/8

02:32 pm

mltx

MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.

Low Report

MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.

Report

11/6

06:33 am

mltx

MoonLake Immunotherapeutics (NASDAQ: MLTX) was upgraded by analysts at Wedbush to a "strong-buy" rating.

Medium Report

MoonLake Immunotherapeutics (NASDAQ: MLTX) was upgraded by analysts at Wedbush to a "strong-buy" rating.

Report

11/6

06:33 am

mltx

MoonLake Immunotherapeutics (NASDAQ: MLTX) was upgraded by analysts at Wedbush to a "strong-buy" rating.

Medium Report

MoonLake Immunotherapeutics (NASDAQ: MLTX) was upgraded by analysts at Wedbush to a "strong-buy" rating.

Report

11/5

08:17 am

mltx

MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $73.00 price target on the stock, down previously from $92.00.

Medium Report

MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $73.00 price target on the stock, down previously from $92.00.

Report

11/5

08:17 am

mltx

MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $73.00 price target on the stock, down previously from $92.00.

Medium Report

MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $73.00 price target on the stock, down previously from $92.00.

Report

11/5

04:41 am

mltx

Rating for MLTX

Low Report

Rating for MLTX

Report

11/5

04:41 am

mltx

Rating for MLTX

Low Report

Rating for MLTX

Report

10/15

08:47 am

mltx

MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.

Low Report

MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.

Report

9/23

08:53 am

mltx

MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.

Medium Report

MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.

Report

9/23

08:22 am

mltx

Rating for MLTX

Medium Report

Rating for MLTX

Report

9/12

08:11 am

mltx

MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $62.00 price target on the stock.

Medium Report

MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $62.00 price target on the stock.

Report

9/12

08:11 am

mltx

MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.

Medium Report

MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.

Report

9/12

05:50 am

mltx

Rating for MLTX

Medium Report

Rating for MLTX

Report

9/12

05:50 am

mltx

Rating for MLTX

Medium Report

Rating for MLTX

Report

9/9

02:14 pm

mltx

MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.

Low Report

MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.

Report

9/9

01:17 pm

mltx

Rating for MLTX

Low Report

Rating for MLTX

Report

8/26

08:03 am

mltx

MoonLake Immunotherapeutics (NASDAQ: MLTX) was downgraded by analysts at Wolfe Research from an "outperform" rating to a "peer perform" rating.

Medium Report

MoonLake Immunotherapeutics (NASDAQ: MLTX) was downgraded by analysts at Wolfe Research from an "outperform" rating to a "peer perform" rating.

Report

8/26

08:03 am

mltx

MoonLake Immunotherapeutics (NASDAQ: MLTX) was downgraded by analysts at Wolfe Research from an "outperform" rating to a "peer perform" rating.

Medium Report

MoonLake Immunotherapeutics (NASDAQ: MLTX) was downgraded by analysts at Wolfe Research from an "outperform" rating to a "peer perform" rating.

Report

8/26

06:29 am

mltx

Rating for MLTX

Medium Report

Rating for MLTX

Report

8/26

06:29 am

mltx

Rating for MLTX

Medium Report

Rating for MLTX

Report

8/26

05:34 am

mltx

MoonLake downgraded to Peer Perform from Outperform at Wolfe Research

Medium Report

MoonLake downgraded to Peer Perform from Outperform at Wolfe Research

Report

8/26

05:34 am

mltx

MoonLake downgraded to Peer Perform from Outperform at Wolfe Research

Medium Report

MoonLake downgraded to Peer Perform from Outperform at Wolfe Research

Report

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.